Comparative Pharmacology
Head-to-head clinical analysis: AZACTAM versus AZACTAM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZACTAM versus AZACTAM IN PLASTIC CONTAINER.
AZACTAM vs AZACTAM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aztreonam is a monobactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 in Gram-negative bacteria, leading to cell death. It is active against aerobic Gram-negative bacilli and has no activity against Gram-positive or anaerobic organisms.
Aztreonam binds to penicillin-binding proteins (PBPs) of susceptible bacteria, inhibiting bacterial cell wall synthesis. It is a monobactam with activity against aerobic gram-negative bacteria.
1-2 g intravenously or intramuscularly every 6-8 hours; maximum 8 g/day.
1-2 g IV/IM every 6-8 hours; maximum 8 g/day.
None Documented
None Documented
Terminal elimination half-life: 1.7-2.2 hours in normal renal function. Prolonged to 6-9 hours in end-stage renal disease; not appreciably removed by hemodialysis.
1.7-2.1 hours (normal renal function); prolonged to 4.2-6.0 hours in ESRD (CrCl <10 mL/min).
Primarily renal (unchanged drug): 60-75% excreted in urine within 8 hours; 10-15% biliary/fecal. Dosage adjustment required in renal impairment.
Primarily renal (75-85% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
Category C
Category C
Monobactam Antibiotic
Monobactam Antibiotic